ArticleFrontiers in immunology2025
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a progressive inflammatory lung disorder influenced by environmental and genetic factors. The rs3741240 polymorphism in the Objective: This study aimed to investigate the functional significance of the Methods: Genotyping of rs3741240 was performed using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP). SCGB1A1 mRNA levels were quantified in healthy controls and among different genotypes using Real-Time PCR. Protein expression was assessed using Western blotting. Results: The genotype and allele frequencies of the 38AA risk genotype were more prevalent in COPD patients than in controls (P = 0.01 and 0.03, respectively). Patients with 38AA genotype exhibited significantly lower FEV1 and FEV1/FVC (P <0.0001). Conclusion: This study is the first to reports in an Indian population that
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.